Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Digital

Aureka Biotechnologies Closes USD 100 Million Series B to Scale AI‑Native Biological Foundation Models, Total Funding Nears USD 200 Million

Fineline Cube Aug 12, 2026
Company Deals

Mabwell Signs Licensing Deals With Southeast Asia Partners for Aflibercept Biosimilar 9MW0813 in Philippines, Vietnam, and Malaysia

Fineline Cube Aug 12, 2026
Company Deals

Sanyou Biopharmaceuticals Signs Strategic Deal With Baiyunshan Xihe to Co‑Develop Novel Radiopharmaceuticals

Fineline Cube Aug 12, 2026
Company Deals

IMPACT Therapeutics Signs Exclusive Deal With Pharmanovia for Senaparib PARP Inhibitor Across 66 Countries Worth Up to EUR 423.5 Million

Fineline Cube Aug 12, 2026
Company Deals

Essex Bio-Technology Signs Strategic Framework With Gunze Medical to Expand FGF-2 Regenerative Medicine Access Across Asia

Fineline Cube Aug 12, 2026
Policy / Regulatory

China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications

Fineline Cube Aug 6, 2026
Company Drug R&D

Insilico Medicine Nominates ISM0900, AI‑Designed Oral Lp(a) Inhibitor, as 9th Preclinical Candidate of 2026

Fineline Cube Aug 12, 2026
Company Drug

Wantai’s 9‑Valent HPV Vaccine Wins Thailand Approval – China’s First and World’s Second 9vHPV Vaccine Expands Into Southeast Asia

Fineline Cube Aug 12, 2026
Company Drug Policy / Regulatory

Hefan Medicine’s Piracetam Production and Marketing Suspended Over GMP Violations

Fineline Cube Dec 4, 2024

The National Drug Alliance Procurement Office has issued a notification to suspend the manufacturing and...

Company Drug

InventisBio’s Oral TYK2 Inhibitor D-2570 Achieves Positive Results in Phase II Psoriasis Study

Fineline Cube Dec 4, 2024

China-based InventisBio (Shanghai) Co., Ltd (SHA: 688382) has announced the successful completion of a Phase...

Company Drug

Shanghai Henlius Biotech’s Serplulimab Approved for First-Line nsNSCLC Treatment in China

Fineline Cube Dec 4, 2024

Shanghai Henlius Biotech Inc., (HKG: 2696) has announced that it has received marketing approval from...

Company Drug

Zhejiang Huahai Pharmaceutical Initiates Clinical Study for HB0056 in New Zealand

Fineline Cube Dec 4, 2024

Zhejiang Huahai Pharmaceutical Co., Ltd. (SHA: 600521), through its subsidiary Shanghai Huaota Biopharmaceutical Co., Ltd.,...

Company Drug

HutchMed and Innovent Biologics’ Fruzaqla-Tyvyt Combo Gets NMPA Conditional Approval for Endometrial Cancer

Fineline Cube Dec 4, 2024

Chinese firms HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) and Innovent Biologics, Inc. (HKG: 1801)...

Company Medical Device

Acotec Scientific’s AcoArt Camellia Receives NMPA Approval for Coronary Artery Disease Treatment

Fineline Cube Dec 4, 2024

China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced that it has received marketing approval...

Company Deals

REGiMMUNE and San Fu Biotech Ink Deal for RGI-2001 Development in Asia

Fineline Cube Dec 3, 2024

Taiwan-based biotechnology company REGiMMUNE Ltd has announced the signing of an out-license agreement with San...

Company Drug

AccurEdit Therapeutics’ ART001 Shows Over 90% TTR Reduction in ATTR Amyloidosis Trial

Fineline Cube Dec 3, 2024

Suzhou-based gene editing specialist AccurEdit Therapeutics has announced positive results from an ongoing investigator-initiated trial...

Company

Sanofi Announces EUR 1 Billion Investment for New Beijing Manufacturing Plant

Fineline Cube Dec 3, 2024

French pharmaceutical company Sanofi (NASDAQ: SNY) has announced plans to invest EUR 1 billion (USD...

Company Drug

Huadong Medicine’s SaiYueXin Biosimilar Accepted for Review by NMPA for Pediatric Psoriasis

Fineline Cube Dec 3, 2024

Huadong Medicine Co., Ltd (SHE: 000963) has announced that the National Medical Products Administration (NMPA)...

Company Deals

Jiangsu Hengrui Pharmaceuticals’ Fluzoparib and Apatinib Gain NMPA Approval for Metastatic Breast Cancer Treatment

Fineline Cube Dec 3, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276), a leading China-based pharmaceutical company, has announced that...

Company Deals

Fangzhou Inc. Expands Partnerships with Tencent Healthcare and Baidu Health at Digital Summit

Fineline Cube Dec 3, 2024

China-based Fangzhou Inc. (HKG: 6086) hosted the “Data and AI: Decoding Digital Engagement” summit in...

Company Deals

MGI Tech Co., Ltd Partners with Universidad de San Martín de Porre for Genomic Sequencing Advancement

Fineline Cube Dec 3, 2024

China-based gene sequencing specialist MGI Tech Co., Ltd has announced a collaboration with the Universidad...

Company Deals

VFLO Medical Partners with Inari Medical to Expand Access in Greater China

Fineline Cube Dec 3, 2024

China-based VFLO Medical, a peripheral vascular device firm incubated by 6 Dimensions Capital, has announced...

Company Drug Medical Device

Uni-Bio Science Group Achieves Milestones in Medical Aesthetics with New Product Approvals

Fineline Cube Dec 3, 2024

China-based Uni-Bio Science Group Limited (HKG: 0690) has announced two significant achievements in the medical...

Company Drug

Ocumen Therapeutics’ OT-301 Phase III Denali Study Surpasses 140 Patient Enrollment in China

Fineline Cube Dec 3, 2024

Chinese ophthalmology specialist Ocumen Therapeutics (HKG: 1477) has announced the enrollment of more than 140...

Company Deals

China Medical System Holdings Secures Exclusive Rights to Atom Therapeutics’ Gout Drug ABP-671

Fineline Cube Dec 3, 2024

China Medical System Holdings (CMS; HKG: 0867) has entered into a licensing agreement with compatriot...

Company Deals Drug

Novartis Secures Global Rights to PTC Therapeutics’ Huntington’s Disease Treatment PTC518

Fineline Cube Dec 3, 2024

Swiss pharmaceutical giant Novartis (NYSE: NVS) has entered into a global license and collaboration agreement...

Company Deals

UCB Partners with BioRay Biopharmaceutical for Bimzelx Commercial Promotion in China

Fineline Cube Dec 3, 2024

Belgium based UCB (EBR: UCB) is fulfilling its commitment to enhance attention to innovative products...

Company Drug

Minghui Pharmaceutical’s MH004 Ointment Meets Primary Endpoints in Atopic Dermatitis Phase III Study

Fineline Cube Dec 2, 2024

Shanghai-based Minghui Pharmaceutical, a late-stage biopharmaceutical company specializing in immunology and oncology, has announced positive...

Posts pagination

1 … 296 297 298 … 707

Recent updates

  • Laekna’s NDA for AKT Inhibitor Afuresertib Accepted by CDE in HR+/HER2‑ Breast Cancer After Qilu Licensing Deal
  • NMPA Approves Geneseeq’s Fandekang NTRK Fusion Detection Kit as Companion Diagnostic for Vcare PharmaTech’s Eratrectinib
  • Aureka Biotechnologies Closes USD 100 Million Series B to Scale AI‑Native Biological Foundation Models, Total Funding Nears USD 200 Million
  • Insilico Medicine Nominates ISM0900, AI‑Designed Oral Lp(a) Inhibitor, as 9th Preclinical Candidate of 2026
  • Haohai Wins NMPA Approval for China’s First Domestic Trifocal Toric Intraocular Lens for Cataract Patients With Astigmatism
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Others

Laekna’s NDA for AKT Inhibitor Afuresertib Accepted by CDE in HR+/HER2‑ Breast Cancer After Qilu Licensing Deal

Company Medical Device

NMPA Approves Geneseeq’s Fandekang NTRK Fusion Detection Kit as Companion Diagnostic for Vcare PharmaTech’s Eratrectinib

Company Deals Digital

Aureka Biotechnologies Closes USD 100 Million Series B to Scale AI‑Native Biological Foundation Models, Total Funding Nears USD 200 Million

Company Drug R&D

Insilico Medicine Nominates ISM0900, AI‑Designed Oral Lp(a) Inhibitor, as 9th Preclinical Candidate of 2026

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.